An #ayurveda medicine, Zingivir-H tablet has got approval for trials on adults tested positive for #Covid-19
An ayurveda medicine, Zingivir-H tablet, used for treating #respiratory #infections, has got approval from the clinical trial registry of India (CTRI)
for clinical trials on adults tested positive for Covid-19. The drug developed
by Kerala-based Pankajakasthuri herbal research foundation and effectively used
for viral fevers, acute viral brochitis and other respiratory infections will
now be tested as a potential medicine for Covid-19 in medical colleges in
India. “Our scientific validations have shown that this drug has strong
anti-viral properties and is effective against respiratory syncytial virus
(RSV) and influenza virus. The RSV is an RNA virus and we expect that it will
be effective against Covid-19, which is also an RNA virus,” said Dr J
Hareendran Nair, Padma Shri awardee and formulator of the drug.
Dr Nair said that several medical colleges have approved the clinical
trials through their ethical committees. “Some of them have already started
trials and the first results are expected to be available by the second week of
May,” he said. He said that the in vitro experiments done at the Rajiv Gandhi
Centre for Biotechnology has proven that there are no side-effects in the human
cell. Subsequently, the approval was received from the institutional ethic
committee (IEC), based on which CTRI, which comes under the Indian council for
medical research (ICMR), gave approval.
Comments
Post a Comment